VIBATIV Pregnancy Registry

• Status: Withdrawn
• Trial end date: 2020-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this registry is to evaluate the outcome of pregnancy in women exposed to VIBATIV at any time during pregnancy. There are no mandated physician visits for the registry.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cumberland Pharmaceuticals; Theravance Biopharma Antibiotics, Inc.
• Treatments: Telavancin

Criteria

Inclusion Criteria:

• Female patients who were exposed to VIBATIV at any time during pregnancy

• Outcome of pregnancy is unknown at the time of enrollment